In a medical landscape where preventative care is framed as the ultimate defense against cardiovascular disease, a jarring new study from the Icahn School of Medicine at Mount Sinai has exposed a critical vulnerability in current clinical practice. According to findings published on November 21 in the Journal of the American College of Cardiology: Advances, the standard tools used by physicians to calculate a patient’s 10-year risk of a heart attack are failing to identify nearly half of the individuals who are at imminent risk of a cardiac event.
This research, which analyzed the clinical pathways of hundreds of heart attack patients, suggests that the reliance on traditional risk-scoring algorithms—specifically the ASCVD (Atherosclerotic Cardiovascular Disease) score and the newer PREVENT tool—may be creating a false sense of security for millions of Americans. By the time many patients report the "classic" symptoms of heart disease, it is often too late for simple preventative measures to be effective.
The Foundation: Understanding Current Risk Assessment Tools
To appreciate the gravity of the Mount Sinai study, one must first understand the "gatekeeper" system currently governing cardiovascular health. For decades, primary care physicians have utilized the ASCVD risk score to make life-altering decisions regarding patient care. Typically applied to adults between the ages of 40 and 75 without a prior history of heart disease, this calculator determines the likelihood of a cardiovascular event within the next decade.
The inputs are standard demographic and clinical markers: age, biological sex, race, systolic blood pressure, total cholesterol levels, HDL cholesterol, diabetes status, and smoking history. Based on the resulting percentage, patients are slotted into four tiers: low risk (under 5%), borderline (5–7.5%), intermediate (7.5–20%), and high (over 20%).
These scores serve as the primary determinants for clinical action. Patients in the high-risk category are routinely prescribed statins and other cardioprotective therapies. Conversely, those categorized as "low" or "borderline"—particularly those who do not report symptoms like chest pain or shortness of breath—are frequently given a clean bill of health and discharged without further diagnostic testing.
The PREVENT tool, a more recent iteration, was designed to improve upon these metrics by incorporating a broader array of variables. However, the study suggests that even these advanced models are failing to capture the nuance of individual physiology.
Chronology of the Investigation: How the Data Was Captured
The study, led by Dr. Amir Ahmadi, a Clinical Associate Professor of Medicine (Cardiology) at Mount Sinai, was structured as a retrospective analysis designed to "reverse engineer" the path to a heart attack.
Between January 2020 and July 2025, researchers tracked 474 patients—all younger than 66 and all without a previously diagnosed history of coronary artery disease—who were admitted to The Mount Sinai Hospital or Mount Sinai Morningside for their first-ever heart attack.
The investigators performed a forensic-style medical review. They collated extensive demographic data, medical histories, lipid profiles, and blood pressure records. Crucially, they mapped the exact timing of the onset of symptoms for every patient. The team then performed a "simulation" of the clinical encounter: they calculated what the patient’s risk score would have been just 48 hours before their heart attack occurred. By placing the patient back in the hypothetical exam room two days prior to their cardiac event, the researchers were able to determine if the patient would have been flagged for intervention under current medical guidelines.
Supporting Data: The Discrepancy Between Risk and Reality
The results of the simulation were stark and, according to the researchers, "fundamentally concerning."
When the ASCVD risk calculator was applied to these patients 48 hours prior to their heart attack, 45% of them would have been classified as "low" or "borderline" risk. In these categories, medical guidelines rarely mandate aggressive diagnostic testing or preventive pharmaceutical intervention.
The results were even more startling when the newer PREVENT tool was applied; under these criteria, more than 61% of the patients would have been categorized as low or borderline risk.
The data further highlighted the danger of relying on symptomatic reporting. The study found that 60% of patients experienced the onset of symptoms—such as chest pain or shortness of breath—fewer than two days before their heart attack. This indicates that for the majority of patients, the disease is "silent" until it is acute. The absence of symptoms, when paired with a low risk score, acts as a systemic blind spot, effectively disqualifying patients from life-saving preventative care until the moment of crisis.
Official Responses and Clinical Perspectives
The lead researchers behind the study were blunt in their assessment of the current medical model. "Our research shows that population-based risk tools often fail to reflect the true risk for many individual patients," said Dr. Amir Ahmadi.
Dr. Ahmadi argued that the current clinical reliance on these calculators as "gatekeepers" is a fundamentally flawed strategy. "If we had seen these patients just two days before their heart attack, nearly half would not have been recommended for further testing or preventive therapy guided by current risk estimate scores and guidelines," he noted.
First author Dr. Anna Mueller, an internal medicine resident at the Icahn School of Medicine at Mount Sinai, emphasized the disconnect between population health and individual patient care. "When we look at heart attacks and trace them backwards, most heart attacks occur in patients in the low or intermediate risk groups," Dr. Mueller explained. "This study highlights that a lower risk score, along with not having classic heart attack symptoms—which is common—is no guarantee of safety on an individual level."
Dr. Mueller stressed that the current framework is optimized for managing large groups but lacks the sensitivity required for individualized medicine. "Our study exposes a major flaw where tools effective for tracking large populations fall short when guiding individualized care."
Implications: A Call for a Paradigm Shift in Cardiology
The implications of this study are profound, potentially necessitating a significant shift in how primary care physicians approach cardiovascular prevention. The central argument made by the Mount Sinai team is that the current model is reactive rather than proactive.
The Shift Toward Atherosclerosis Imaging
The authors argue that if we are to prevent the "silent" progression of heart disease, we must move away from the obsession with 10-year risk calculators and move toward direct visualization of the disease process.
"It may be time to fundamentally reconsider this model and move toward atherosclerosis imaging to identify the silent plaque—early atherosclerosis—before it has a chance to rupture," Dr. Ahmadi suggested.
By utilizing imaging technology to detect the presence of plaque directly, physicians could identify patients who are at risk long before they reach a critical threshold of "risk points" on a chart. This approach would shift the diagnostic burden from the patient’s ability to report symptoms to the clinician’s ability to visualize the underlying pathology.
The Need for Future Research
While the study provides a compelling case for change, the researchers acknowledge that the transition to an imaging-first model will require more extensive study. Refining these methods to ensure that imaging is used appropriately and cost-effectively will be a major priority for the next generation of cardiovascular research.
Furthermore, the study underscores the need for better integration of individual patient history beyond the standard "Big Eight" risk factors. The fact that nearly two-thirds of patients under the PREVENT guidelines would have been missed is a sobering statistic that suggests current preventive frameworks may be under-diagnosing the true scope of cardiovascular vulnerability in the general population.
Conclusion: The Path Forward
The study from Mount Sinai serves as a wake-up call for both providers and patients. The reliance on risk scores—while convenient and statistically validated for broad population management—can create a dangerous sense of complacency in the exam room. When a low-risk score is combined with a lack of overt symptoms, it can lead to a fatal missed opportunity for early intervention.
As medicine moves toward a more personalized, data-driven future, the transition from estimating risk to detecting actual physical markers of disease appears to be the most promising path forward. Until such a shift is formalized into clinical guidelines, the message from the researchers is clear: the absence of symptoms is not the presence of health. Patients and physicians alike must remain vigilant, questioning the accuracy of risk calculators when they fail to account for the silent, often invisible, buildup of atherosclerosis that precedes a heart attack.
In the wake of this report, the medical community will likely face pressure to reassess the tools it uses to define "low risk," potentially ushering in an era where earlier, more aggressive diagnostic imaging becomes the standard of care for millions.
